MedTrace Logo

The Resting-state EEG Gamma Oscillations in Alzheimer's Disease

NCT05989087 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2023-08-22

No results posted yet for this study

Summary

The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology. The present study aims to investigate resting-state gamma activity changes in Cerebrospinal fluid (CSF)-proven early-onset Alzheimer's disease (EOAD) patients with a holistic approach that employs structural and functional brain neuroimaging techniques, and neuropsychological aspects.

Conditions

  • Alzheimer Disease, Early Onset

Interventions

DIAGNOSTIC_TEST

CSF

Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.

Sponsors & Collaborators

  • Görsev Yener, MD, PhD

    lead OTHER

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-07
Primary Completion
2016-01-02
Completion
2019-04-05

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05989087 on ClinicalTrials.gov